company background image
A166480 logo

CORESTEMCHEMON KOSDAQ:A166480 Stock Report

Last Price

₩4.40k

Market Cap

₩107.2b

7D

-70.2%

1Y

-32.4%

Updated

24 Dec, 2024

Data

Company Financials

CORESTEMCHEMON Inc.

KOSDAQ:A166480 Stock Report

Market Cap: ₩107.2b

A166480 Stock Overview

A bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. More details

A166480 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

CORESTEMCHEMON Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CORESTEMCHEMON
Historical stock prices
Current Share Price₩4,400.00
52 Week High₩15,610.00
52 Week Low₩4,280.00
Beta0.82
1 Month Change-61.74%
3 Month Change-65.22%
1 Year Change-32.41%
3 Year Change-75.35%
5 Year Change-51.38%
Change since IPO-89.42%

Recent News & Updates

Recent updates

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Dec 09
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

Nov 01
Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

Sep 24
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

Aug 03
Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling You

Jun 08
What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling You

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry

Mar 05
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry

Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

Apr 12
Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns

Feb 16
If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns

Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

Dec 25
Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

Shareholder Returns

A166480KR BiotechsKR Market
7D-70.2%-1.2%-0.9%
1Y-32.4%16.3%-9.0%

Return vs Industry: A166480 underperformed the KR Biotechs industry which returned 16.1% over the past year.

Return vs Market: A166480 underperformed the KR Market which returned -9% over the past year.

Price Volatility

Is A166480's price volatile compared to industry and market?
A166480 volatility
A166480 Average Weekly Movement18.9%
Biotechs Industry Average Movement8.8%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.7%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A166480's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A166480's weekly volatility has increased from 12% to 19% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aKyung-Suk Kimwww.corestem.com

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases.

CORESTEMCHEMON Inc. Fundamentals Summary

How do CORESTEMCHEMON's earnings and revenue compare to its market cap?
A166480 fundamental statistics
Market cap₩107.18b
Earnings (TTM)-₩37.94b
Revenue (TTM)₩28.88b

3.7x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A166480 income statement (TTM)
Revenue₩28.88b
Cost of Revenue₩31.74b
Gross Profit-₩2.86b
Other Expenses₩35.09b
Earnings-₩37.94b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.56k
Gross Margin-9.90%
Net Profit Margin-131.37%
Debt/Equity Ratio165.6%

How did A166480 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 04:40
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CORESTEMCHEMON Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Byung Hwa HanEugene Investment & Securities Co Ltd.
Jiyong LeeShinhan Investment Corp.
Choongwoo SeoSK Securities Co., Ltd.